Corporate Compliance And Transparency In The Pharma Sector, 18-19 October 2012, Prague, Czech Republic

Date: Jul-31-2012Stricter regulations and various requirements in pharma ensure that the industry is ever-evolving and moving forward. From improving the quality process, reducing costs and remarkable progress in R&D, now is the optimal time to look at the transparency deficiencies in the pharma sector. In which areas do you think increased transparency would be most welcome?

2-DAY conference by Fleming Europe will look at this topic thoroughly.

CORPORATE COMPLIANCE & TRANSPARENCY IN THE PHARMA SECTOR

18 -19 October 2012, Prague, Czech Republic

17 SPEAKERS from pharma and biotech companies, law firms, audit companies, governmental bodies and institutions, regulatory authorities, and non-profit organizations will gather with a clear purpose - to share their knowledge and give advice in order to improve public trust in the pharmaceutical sector.

13 PRESENTATIONS will introduce to the attendees the main transparency and compliance issues comprising different perspectives. EFPIA will present the industry perspective on the current state of pharmaceutical transparency in Europe, including an overview of European anti-bribery issues and efforts to prevent them, compliance requirements for the upcoming years and their impact on pharma, as well as promoting trust and transparency in pharmaceutical companies. A special insight into the revision of the transparency directive, with the aim of making the pharmaceutical transparency initiative more successful, will be presented by the European Commission.

3 PANEL DISCUSSIONS will dominate the second conference day. With the focus on achieving corporate compliance in the CEE/CIS region, participants will have the opportunity to share their own knowledge and experience with special features of the CEE/CIS compliance environment, latest developments in transparency and compliance legislation in this region, and special drivers in CEE/CIS compliance. Harmonized legislation in the "new" EU member states vs. countries on their way towards harmonization and the most effective anti-corruption measures in the emerging countries of this region will be discussed as well.

1 ROUND-TABLE DISCUSSION dividing the audience into smaller groups will provide attendees with a unique opportunity to discuss the aggregate spend tracking issues of key concern - the impact on interactions of the pharma sector with the healthcare practitioners and the impact on how institutions and regulatory agencies look at the healthcare practitioners employed by them or working on advisory groups.

COUNTLESS NETWORKING OPPORTUNITIES & REASONS TO ATTEND:
Understand the current anti-corruption environment in Europe
Hear about "compliance requirements" for compliance programs with a focus on their implementation in organizational context
Hear from Novo Nordisk Russia about the FAS issue and understand the lessons learned for multinational pharma companies doing business in Russia
Understand how to create an effective "tone from middle" strategy
Take part in a focused round-table discussion and interactive panel sessions

Did you find your reason to attend? Do not hesitate and join us in Prague. For detailed information please request the agenda http://pharma.flemingeurope.com/corporate-compliance/request-agenda
Courtesy: Medical News Today Note: Any medical information available in this news section is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional.